Wegovy is tailored for chronic weight management, often at higher doses, while Ozempic is aimed at improving blood sugar control in type 2 diabetes patients, often at lower doses
In November 2023, the FDA approved Zepbound for weight loss
For most people, the tiredness peaks during initial adjustment weeks and after dose increases, then improves substantially within 3 to 4 weeks
Mechanistically, any factor leading to abnormalities in the insulin signaling pathway leads to the development of IR in the host, including insulin receptor abnormalities, disturbances in the internal environment (regarding inflammation, hypoxia, lipotoxicity, and immunity), metabolic function of the liver and organelles, and other abnormalities